Unknown

Dataset Information

0

MiR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.


ABSTRACT: Drug-tolerance is an acute defense response prior to a fully drug-resistant state and tumor relapse, however there are few therapeutic agents targeting drug-tolerance in the clinic. Here we show that miR-147b initiates a reversible tolerant-state to the EGFR inhibitor osimertinib in non-small cell lung cancer. With miRNA-seq analysis we find that miR-147b is the most upregulated microRNA in osimertinib-tolerant and EGFR mutated lung cancer cells. Whole transcriptome analysis of single-cell derived clones reveals a link between osimertinib-tolerance and pseudohypoxia responses irrespective of oxygen levels. Further metabolomics and genetic studies demonstrate that osimertinib-tolerance is driven by miR-147b repression of VHL and succinate dehydrogenase linked to the tricarboxylic acid cycle and pseudohypoxia pathways. Finally, pretreatment with a miR-147b inhibitor delays osimertinib-associated drug tolerance in patient-derived three-dimensional (3D) structures. This link between miR-147b and tricarboxylic acid cycle may provide promising targets for preventing tumor relapse.

SUBMITTER: Zhang WC 

PROVIDER: S-EPMC6750230 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.

Zhang Wen Cai WC   Wells Julie M JM   Chow Kin-Hoe KH   Huang He H   Yuan Min M   Saxena Tanvi T   Melnick Mary Ann MA   Politi Katerina K   Asara John M JM   Costa Daniel B DB   Bult Carol J CJ   Slack Frank J FJ  

Nature metabolism 20190408 4


Drug-tolerance is an acute defense response prior to a fully drug-resistant state and tumor relapse, however there are few therapeutic agents targeting drug-tolerance in the clinic. Here we show that miR-147b initiates a reversible tolerant-state to the EGFR inhibitor osimertinib in non-small cell lung cancer. With miRNA-seq analysis we find that miR-147b is the most upregulated microRNA in osimertinib-tolerant and <i>EGFR</i> mutated lung cancer cells. Whole transcriptome analysis of single-cel  ...[more]

Similar Datasets

| S-EPMC10281470 | biostudies-literature
| S-EPMC7694553 | biostudies-literature
| S-EPMC10831602 | biostudies-literature
| S-EPMC8654791 | biostudies-literature
| S-EPMC3441733 | biostudies-other
| S-ECPF-GEOD-33247 | biostudies-other
| S-EPMC7852548 | biostudies-literature
| S-EPMC5898814 | biostudies-other
| S-EPMC5731346 | biostudies-literature
| S-EPMC6935159 | biostudies-literature